Compare ALEMBIC PHARMA with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA DIVIS LABORATORIES ALEMBIC PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 16.4 57.6 28.5% View Chart
P/BV x 6.5 15.4 42.4% View Chart
Dividend Yield % 0.6 0.4 147.2%  

Financials

 ALEMBIC PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
DIVIS LABORATORIES
Mar-19
ALEMBIC PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs6641,639 40.5%   
Low Rs4121,115 37.0%   
Sales per share (Unadj.) Rs208.7186.3 112.0%  
Earnings per share (Unadj.) Rs31.051.0 60.8%  
Cash flow per share (Unadj.) Rs37.157.3 64.7%  
Dividends per share (Unadj.) Rs5.5016.00 34.4%  
Dividend yield (eoy) %1.01.2 88.0%  
Book value per share (Unadj.) Rs144.2261.8 55.1%  
Shares outstanding (eoy) m188.52265.47 71.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.67.4 34.9%   
Avg P/E ratio x17.427.0 64.2%  
P/CF ratio (eoy) x14.524.0 60.4%  
Price / Book Value ratio x3.75.3 70.9%  
Dividend payout %17.731.4 56.5%   
Avg Mkt Cap Rs m101,461365,592 27.8%   
No. of employees `000NA11.8 0.0%   
Total wages/salary Rs m7,4675,423 137.7%   
Avg. sales/employee Rs ThNM4,175.1-  
Avg. wages/employee Rs ThNM457.7-  
Avg. net profit/employee Rs ThNM1,141.8-  
INCOME DATA
Net Sales Rs m39,34749,463 79.5%  
Other income Rs m941,556 6.0%   
Total revenues Rs m39,44151,019 77.3%   
Gross profit Rs m8,73618,718 46.7%  
Depreciation Rs m1,1521,689 68.2%   
Interest Rs m18435 526.0%   
Profit before tax Rs m7,49318,551 40.4%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5685,023 31.2%   
Profit after tax Rs m5,84413,527 43.2%  
Gross profit margin %22.237.8 58.7%  
Effective tax rate %20.927.1 77.3%   
Net profit margin %14.927.3 54.3%  
BALANCE SHEET DATA
Current assets Rs m19,57746,501 42.1%   
Current liabilities Rs m14,8968,468 175.9%   
Net working cap to sales %11.976.9 15.5%  
Current ratio x1.35.5 23.9%  
Inventory Days Days90131 68.6%  
Debtors Days Days4586 52.8%  
Net fixed assets Rs m27,09725,797 105.0%   
Share capital Rs m377531 71.0%   
"Free" reserves Rs m26,81168,962 38.9%   
Net worth Rs m27,18869,493 39.1%   
Long term debt Rs m4,9930-   
Total assets Rs m47,77880,383 59.4%  
Interest coverage x41.7531.0 7.9%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.80.6 133.8%   
Return on assets %12.616.9 74.8%  
Return on equity %21.519.5 110.4%  
Return on capital %23.626.7 88.2%  
Exports to sales %00-   
Imports to sales %024.6 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA12,187 0.0%   
Fx inflow Rs m19,45341,238 47.2%   
Fx outflow Rs m6,06512,405 48.9%   
Net fx Rs m13,38828,833 46.4%   
CASH FLOW
From Operations Rs m8,1209,543 85.1%  
From Investments Rs m-7,556-6,854 110.2%  
From Financial Activity Rs m590-2,459 -24.0%  
Net Cashflow Rs m1,153230 502.3%  

Share Holding

Indian Promoters % 74.1 52.0 142.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 11.8 24.6%  
FIIs % 9.1 19.0 47.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 17.2 80.8%  
Shareholders   49,328 31,796 155.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   ALEMBIC  SUN PHARMA  IPCA LABS  FDC  AUROBINDO PHARMA  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (3QFY21); Net Profit Up 27.9% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 13.8% (Quarterly Result Update)

Jan 19, 2021 | Updated on Jan 19, 2021

For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)

Oct 23, 2020 | Updated on Oct 23, 2020

For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


May 7, 2021 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS